The attraction of listing in the US for innovative companies is clear but the heads of the Swiss Biotech Association tell Scrip that start-ups should remember the advantages of playing at home and not waste too much energy and time on worrying about being on the NASDAQ.

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

Teleflex markets the UroLift minimally invasive system for managing symptomatic benign prostate hyperplasia. Palette sells five urology products, including Barrigel spacer gel for prostate radiotherapy.

An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.